Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Vanda Pharmaceuticals (VNDA) FCF Margin (2016 - 2025)

Vanda Pharmaceuticals (VNDA) has disclosed FCF Margin for 16 consecutive years, with 51.59% as the latest value for Q4 2025.

  • Quarterly FCF Margin fell 4777.0% to 51.59% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 51.1% through Dec 2025, down 4293.0% year-over-year, with the annual reading at 51.1% for FY2025, 4293.0% down from the prior year.
  • FCF Margin hit 51.59% in Q4 2025 for Vanda Pharmaceuticals, up from 56.5% in the prior quarter.
  • In the past five years, FCF Margin ranged from a high of 50.8% in Q1 2023 to a low of 67.11% in Q1 2025.
  • Historically, FCF Margin has averaged 4.33% across 5 years, with a median of 1.39% in 2022.
  • Biggest five-year swings in FCF Margin: surged 4421bps in 2023 and later crashed -8304bps in 2025.
  • Year by year, FCF Margin stood at 38.92% in 2021, then plummeted by -64bps to 14.19% in 2022, then crashed by -162bps to 8.8% in 2023, then soared by 57bps to 3.82% in 2024, then tumbled by -1251bps to 51.59% in 2025.
  • Business Quant data shows FCF Margin for VNDA at 51.59% in Q4 2025, 56.5% in Q3 2025, and 29.57% in Q2 2025.